Hostname: page-component-78c5997874-dh8gc Total loading time: 0 Render date: 2024-11-07T21:10:04.500Z Has data issue: false hasContentIssue false
  • English
  • Français

Infantile recurrent respiratory papillomatosis: review of adjuvant therapies

Published online by Cambridge University Press:  02 September 2021

A Patel  and
N Orban
A Patel*
Affiliation:
ENT Department, Royal London Hospital, Whitechapel Road, Whitechapel, LondonE1 1FR, UK
N Orban
Affiliation:
ENT Department, Royal London Hospital, Whitechapel Road, Whitechapel, LondonE1 1FR, UK
*
Author for correspondence: Dr Ankit Patel, ENT Department, Royal London Hospital, LondonE1 1FR, UK E-mail: [email protected]
Get access Rights & Permissions [Opens in a new window]

Abstract

Background

Recurrent respiratory papillomatosis is a potentially life-threatening condition characterised by the growth of exophytic lesions within the larynx and trachea. The principal aim of management is maintenance of an adequate airway by surgical debulking. Several adjuvant therapies have been used to varying effect to reduce the burden of this disease and increase the interval between debulking procedures. The most severe cases present in children aged under three years, who are therefore most likely to need adjuvant therapies. The current evidence base on adjuvant treatments relating to children who present aged under three years has been reviewed.

Methods

A literature review of articles in Cochrane, PubMed and Embase databases was carried out. Given the rarity of the condition in this age group, all the literature relates to case reports and case series.

Results and conclusion

The following adjuvant therapies have been used in children who presented under three years of age: quadrivalent human papilloma virus vaccine, intralesional cidofovir, pegylated interferon, alpha-interferon, cimetidine and cetuximab.

Keywords

Laryngeal PapillomatosisRecurrent Respiratory PapillomatosisAirway ObstructionPediatricsCidofovirPapillomavirus Vaccines
Type
Main Articles
Information
The Journal of Laryngology & Otology , Volume 135 , Issue 11 , November 2021 , pp. 958 - 963
Copyright
Copyright © The Author(s), 2021. Published by Cambridge University Press

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

Footnotes

Dr A Patel takes responsibility for the integrity of the content of the paper

References

Wiatrak, BJ. Overview of recurrent respiratory papillomatosis. Curr Opin Otolaryngol Head Neck Surg 2003;11:433–41CrossRefGoogle ScholarPubMed
Derkay, CS. Task force on recurrent respiratory papillomas. A preliminary report. Arch Otolaryngol Head Neck Surg 1995;121:1386–91CrossRefGoogle ScholarPubMed
Larson, DA, Derkay, CS. Epidemiology of recurrent respiratory papillomatosis. APMIS 2010;118:450–4CrossRefGoogle ScholarPubMed
Armstrong, LR, Derkay, CS, Reeves, WC. Initial results from the national registry for juvenile-onset recurrent respiratory papillomatosis. RRP Task Force. Arch Otolaryngol Head Neck Surg 1999;125:743–8CrossRefGoogle Scholar
Derkay, CS, Darrow, DH. Recurrent respiratory papillomatosis of the larynx: current diagnosis and treatment. Otolaryngol Clin North Am 2000;33:1127–42CrossRefGoogle ScholarPubMed
Mounts, P, Shah, KV, Kashima, H. Viral etiology of juvenile- and adult-onset squamous papilloma of the larynx. Proc Natl Acad Sci U S A 1982;79:5425–9CrossRefGoogle ScholarPubMed
Silverberg, MJ, Thorsen, P, Lindeberg, H, Grant, LA, Shah, KV. Condyloma in pregnancy is strongly predictive of juvenile-onset recurrent respiratory papillomatosis. Obstet Gynecol 2003;101:645–52Google ScholarPubMed
Shah, K, Kashima, H, Polk, BF, Shah, F, Abbey, H, Abramson, A. Rarity of cesarean delivery in cases of juvenile-onset respiratory papillomatosis. Obstet Gynecol 1986;68:795–9Google ScholarPubMed
Loyo, M, Pai, SI, Netto, GJ, Tunkel, DE. Aggressive recurrent respiratory papillomatosis in a neonate. Int J Pediatr Otorhinolaryngol 2008;72:917–20CrossRefGoogle ScholarPubMed
Shah, KV, Stern, WF, Shah, FK, Bishai, D, Kashima, HK. Risk factors for juvenile onset recurrent respiratory papillomatosis. Pediatr Infect Dis J 1998;17:372–6CrossRefGoogle ScholarPubMed
Solomon, D, Smith, RR, Kashima, HK, Leventhal, BG. Malignant transformation in non-irradiated recurrent respiratory papillomatosis. Laryngoscope 1985;95:900–4CrossRefGoogle ScholarPubMed
Soma, MA, Albert, DM. Cidofovir: to use or not to use? Curr Opin Otolaryngol Head Neck Surg 2008;16:86–90CrossRefGoogle ScholarPubMed
Clamp, PJ, Saunders, MW. Systematic review of intralesional cidofovir dosing regimens in the treatment of recurrent respiratory papillomatosis. Int J Pediatr Otorhinolaryngol 2013;77:323–8CrossRefGoogle ScholarPubMed
Shehab, N, Sweet, BV, Hogikyan, ND. Cidofovir for the treatment of recurrent respiratory papillomatosis: a review of the literature. Pharmacotherapy 2005;25:977–89CrossRefGoogle ScholarPubMed
Fusconi, M, Grasso, M, Greco, A, Gallo, A, Campo, F, Remacle, M et al. Recurrent respiratory papillomatosis by HPV: review of the literature and update on the use of cidofovir. Acta Otorhinolaryngol Ital 2014;34:375–81Google ScholarPubMed
Ivancic, R, Iqbal, H, deSilva, B, Pan, Q, Matrka, L. Current and future management of recurrent respiratory papillomatosis. Laryngoscope Investig Otolaryngol 2018;3:22–3410.1002/lio2.132CrossRefGoogle ScholarPubMed
Harcourt, JP, Worley, G, Leighton, SE. Cimetidine treatment for recurrent respiratory papillomatosis. Int J Pediatr Otorhinolaryngol 1999;51:109–13CrossRefGoogle ScholarPubMed
Maunsell, R, Bellomo-Brandao, MA. Pegylated interferon for treating severe recurrent respiratory papillomatosis in a child: case report. Sao Paulo Med J 2018;136:376–81CrossRefGoogle Scholar
Saleh, EM. Complications of treatment of recurrent laryngeal papillomatosis with the carbon dioxide laser in children. J Laryngol Otol 1992;106:715–18CrossRefGoogle ScholarPubMed
Schraff, S, Derkay, CS, Burke, B, Lawson, L. American Society of Pediatric Otolaryngology members' experience with recurrent respiratory papillomatosis and the use of adjuvant therapy. Arch Otolaryngol Head Neck Surg 2004;130:1039–42CrossRefGoogle ScholarPubMed
Chadha, NK, James, A. Adjuvant antiviral therapy for recurrent respiratory papillomatosis. Cochrane Database Syst Rev 2012;(12):CD005053Google ScholarPubMed
Katsuta, T, Miyaji, Y, Offit, PA, Feemster, KA. Treatment with quadrivalent human papillomavirus vaccine for juvenile-onset recurrent respiratory papillomatosis: case report and review of the literature. J Pediatric Infect Dis Soc 2017;6:380–5CrossRefGoogle ScholarPubMed
Arbyn, M, Xu, L. Efficacy and safety of prophylactic HPV vaccines. A Cochrane review of randomized trials. Expert Rev Vaccines 2018;17:1085–91Google ScholarPubMed
Mudry, P, Vavrina, M, Mazanek, P, Machalova, M, Litzman, J, Sterba, J. Recurrent laryngeal papillomatosis: successful treatment with human papillomavirus vaccination. Arch Dis Child 2011;96:476–7CrossRefGoogle ScholarPubMed
Meszner, Z, Jankovics, I, Nagy, A, Gerlinger, I, Katona, G. Recurrent laryngeal papillomatosis with oesophageal involvement in a 2 year old boy: successful treatment with the quadrivalent human papillomatosis vaccine. Int J Pediatr Otorhinolaryngol 2015;79:262–6CrossRefGoogle Scholar
Forster, G, Boltze, C, Seidel, J, Pawlita, M, Muller, A. Juvenile laryngeal papillomatosis--immunisation with the polyvalent vaccine Gardasil [in German]. Laryngorhinootologie 2008;87:796–9Google Scholar
Young, DL, Moore, MM, Halstead, LA. The use of the quadrivalent human papillomavirus vaccine (Gardasil) as adjuvant therapy in the treatment of recurrent respiratory papilloma. J Voice 2015;29:223–9CrossRefGoogle ScholarPubMed
Tjon Pian Gi, RE, Ilmarinen, T, van den Heuvel, ER, Aaltonen, LM, Andersen, J, Brunings, JW et al. Safety of intralesional cidofovir in patients with recurrent respiratory papillomatosis: an international retrospective study on 635 RRP patients. Eur Arch Otorhinolaryngol 2013;270:1679–87CrossRefGoogle ScholarPubMed
Naiman, AN, Roger, G, Gagnieu, MC, Bordenave, J, Mathaut, S, Ayari, S et al. Cidofovir plasma assays after local injection in respiratory papillomatosis. Laryngoscope 2004;114:1151–6CrossRefGoogle ScholarPubMed
Dikkers, FG. Intralesional cidofovir does not increase the risk of laryngeal dysplasia or laryngeal carcinoma. Int J Pediatr Otorhinolaryngol 2008;72:1581–2; author reply 1583CrossRefGoogle ScholarPubMed
Milczuk, HA. Intralesional cidofovir for the treatment of severe juvenile recurrent respiratory papillomatosis: long-term results in 4 children. Otolaryngol Head Neck Surg 2003;128:788–94CrossRefGoogle ScholarPubMed
Pransky, SM, Brewster, DF, Magit, AE, Kearns, DB. Clinical update on 10 children treated with intralesional cidofovir injections for severe recurrent respiratory papillomatosis. Arch Otolaryngol Head Neck Surg 2000;126:1239–43CrossRefGoogle ScholarPubMed
Peyton Shirley, W, Wiatrak, B. Is cidofovir a useful adjunctive therapy for recurrent respiratory papillomatosis in children? Int J Pediatr Otorhinolaryngol 2004;68:413–18CrossRefGoogle ScholarPubMed
Chung, BJ, Akst, LM, Koltai, PJ. 3.5-Year follow-up of intralesional cidofovir protocol for pediatric recurrent respiratory papillomatosis. Int J Pediatr Otorhinolaryngol 2006;70:1911–17CrossRefGoogle ScholarPubMed
Bielecki, I, Mniszek, J, Cofala, M. Intralesional injection of cidofovir for recurrent respiratory papillomatosis in children. Int J Pediatr Otorhinolaryngol 2009;73:681–4CrossRefGoogle ScholarPubMed
Boltezar, IH, Bahar, MS, Zargi, M, Gale, N, Maticic, M, Poljak, M. Adjuvant therapy for laryngeal papillomatosis. Acta Dermatovenerol Alp Pannonica Adriat 2011;20:175–80Google ScholarPubMed
Akst, LM, Lee, W, Discolo, C, Knott, D, Younes, A, Koltai, PJ. Stepped-dose protocol of cidofovir therapy in recurrent respiratory papillomatosis in children. Arch Otolaryngol Head Neck Surg 2003;129:841–6CrossRefGoogle ScholarPubMed
Durvasula, VS, Richter, GT. Intralesional cidofovir as adjuvant for the successful management of aggressive respiratory papillomatosis in an infant. Int J Pediatr Otorhinolaryngol 2013;77:1912–15CrossRefGoogle ScholarPubMed
Ksiazek, J, Prager, JD, Sun, GH, Wood, RE, Arjmand, EM. Inhaled cidofovir as an adjuvant therapy for recurrent respiratory papillomatosis. Otolaryngol Head Neck Surg 2011;144:639–41CrossRefGoogle ScholarPubMed
Dikkers, FG. Letter to the editor regarding "systematic review of intralesional cidofovir dosing regimens in the treatment of recurrent respiratory papillomatosis". Int J Pediatr Otorhinolaryngol 2013;77:1789CrossRefGoogle Scholar
Healy, GB, Gelber, RD, Trowbridge, AL, Grundfast, KM, Ruben, RJ, Price, KN. Treatment of recurrent respiratory papillomatosis with human leukocyte interferon. Results of a multicenter randomized clinical trial. N Engl J Med 1988;319:401–7Google ScholarPubMed
Bostrom, B, Sidman, J, Marker, S, Lander, T, Drehner, D. Gefitinib therapy for life-threatening laryngeal papillomatosis. Arch Otolaryngol Head Neck Surg 2005;131:64–7CrossRefGoogle ScholarPubMed